FMO4

Summary

FMO4 (flavin containing dimethylaniline monoxygenase 4, HGNC:3772) is a protein-coding gene on chromosome 1q24.3, encoding Dimethylaniline monooxygenase [N-oxide-forming] 4 (P31512). This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides.

Metabolic N-oxidation of diet-derived amino-trimethylamine (TMA) is mediated by flavin-containing monooxygenase and is subject to an inherited FMO3 polymorphism in man. This results in a small subpopulation with reduced TMA N-oxidation capacity and causes fish odor syndrome (Trimethylaminuria). Three forms of the enzyme are encoded by genes clustered in the 1q23-q25 region. Flavin-containing monooxygenases are NADPH-dependent flavoenzymes that catalyzes the oxidation of soft nucleophilic heteroatom centers in drugs, pesticides, and xenobiotics.

Source: NCBI Gene 2329 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 98 total
• Phenotypes (HPO): 1
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency dosage sensitivity unlikely, triplosensitivity no evidence
• MANE Select transcript: NM_002022

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3772
Approved symbol	FMO4
Name	flavin containing dimethylaniline monoxygenase 4
Location	1q24.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000076258
Ensembl biotype	protein_coding
OMIM	136131
Entrez	2329

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 12 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000367749, ENST00000462992, ENST00000475780, ENST00000480136, ENST00000497228, ENST00000853709, ENST00000853710, ENST00000853711, ENST00000853712, ENST00000853713, ENST00000853714, ENST00000853715, ENST00000853716, ENST00000919758, ENST00000959333, ENST00000959334

RefSeq mRNA: 1 — MANE Select: NM_002022 NM_002022

CCDS: CCDS1295

Canonical transcript exons

ENST00000367749 — 10 exons

Exon	Start	End
ENSE00000789750	171332709	171332908
ENSE00000789751	171334411	171334763
ENSE00001022028	171316186	171316327
ENSE00001445542	171341413	171342084
ENSE00003548928	171323004	171323192
ENSE00003587017	171319818	171319957
ENSE00003679873	171331640	171331782
ENSE00003680340	171324138	171324300
ENSE00003681912	171337356	171337425
ENSE00003842448	171314183	171314413

Expression profiles

Bgee: expression breadth ubiquitous, 202 present calls, max score 89.40.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.4208 / max 161.6560, expressed in 177 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6605	1.7960	864
6606	1.4397	704
6596	1.4208	177
6604	0.6397	377
6594	0.0709	36
6595	0.0695	33

Top tissues by expression

270 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nephron tubule	UBERON:0001231	89.40	gold quality
right lobe of liver	UBERON:0001114	88.07	gold quality
ileal mucosa	UBERON:0000331	87.88	gold quality
liver	UBERON:0002107	86.99	gold quality
kidney epithelium	UBERON:0004819	86.92	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.46	gold quality
adult mammalian kidney	UBERON:0000082	85.37	gold quality
kidney	UBERON:0002113	84.71	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.55	gold quality
renal glomerulus	UBERON:0000074	83.25	gold quality
cortex of kidney	UBERON:0001225	82.67	gold quality
metanephric glomerulus	UBERON:0004736	82.47	gold quality
ascending aorta	UBERON:0001496	81.41	gold quality
thoracic aorta	UBERON:0001515	81.29	gold quality
descending thoracic aorta	UBERON:0002345	81.24	gold quality
hair follicle	UBERON:0002073	81.00	gold quality
calcaneal tendon	UBERON:0003701	80.72	gold quality
palpebral conjunctiva	UBERON:0001812	79.81	gold quality
apex of heart	UBERON:0002098	79.71	gold quality
mucosa of transverse colon	UBERON:0004991	79.63	gold quality
mucosa of paranasal sinus	UBERON:0005030	79.53	silver quality
aorta	UBERON:0000947	79.22	gold quality
left coronary artery	UBERON:0001626	79.06	gold quality
pancreatic ductal cell	CL:0002079	79.00	silver quality
germinal epithelium of ovary	UBERON:0001304	78.45	gold quality
right uterine tube	UBERON:0001302	78.17	gold quality
coronary artery	UBERON:0001621	78.13	gold quality
popliteal artery	UBERON:0002250	77.80	gold quality
tibial artery	UBERON:0007610	77.77	gold quality
duodenum	UBERON:0002114	77.66	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.63

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOS

miRNA regulators (miRDB)

42 targeting FMO4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4531	99.99	69.70	3181
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-570-3P	99.96	72.41	4910
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-10395-5P	99.86	67.35	676
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-154-3P	99.50	70.05	831
HSA-MIR-487A-3P	99.50	69.95	840
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-6797-3P	99.17	66.94	668
HSA-MIR-892C-5P	99.16	70.56	2116
HSA-MIR-6510-5P	99.14	66.59	1081

Functional genomics

ClinGen dosage: haploinsufficiency 40 (dosage sensitivity unlikely), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 1)

• Data show a compelling visual demonstration of the isoform-specific localization patterns of FMO1, -3, and -4 in the rat liver and kidney and the first evidence for expression of FMO4 at the protein level in mouse and human liver and kidney microsomes. (PMID:19307449)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
mus_musculus	Fmo4	ENSMUSG00000026692
rattus_norvegicus	Fmo4	ENSRNOG00000003400
caenorhabditis_elegans		WBGENE00001476
caenorhabditis_elegans		WBGENE00001478
caenorhabditis_elegans		WBGENE00001480
caenorhabditis_elegans	C01H6.4	WBGENE00007254
caenorhabditis_elegans	C46H11.2	WBGENE00016728

Paralogs (5): FMO3 (ENSG00000007933), FMO1 (ENSG00000010932), FMO2 (ENSG00000094963), FOXRED2 (ENSG00000100350), FMO5 (ENSG00000131781)

Protein

Protein identifiers

Dimethylaniline monooxygenase [N-oxide-forming] 4 — P31512 (reviewed: P31512)

Alternative names: Dimethylaniline oxidase 4, Hepatic flavin-containing monooxygenase 4

All UniProt accessions (1): P31512

UniProt curated annotations — full annotation on UniProt →

Function. This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides.

Subcellular location. Microsome membrane. Endoplasmic reticulum membrane.

Tissue specificity. Liver.

Similarity. Belongs to the FMO family.

RefSeq proteins (1): NP_002013* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000960	Flavin_mOase	Family
IPR002256	Flavin_mOase_4	Family
IPR020946	Flavin_mOase-like	Family
IPR036188	FAD/NAD-bd_sf	Homologous_superfamily
IPR050346	FMO-like	Family

Pfam: PF00743

Enzyme classification (BRENDA):

• EC 1.14.13.8 — flavin-containing monooxygenase (BRENDA: 30 organisms, 458 substrates, 77 inhibitors, 260 Km, 123 kcat entries)

Substrate kinetics (BRENDA)

72 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
METHIMAZOLE	0.007–0.5758	18
TAMOXIFEN	0.0013–0.121	15
INDOLE	0.005–0.9	13
BENZYDAMINE	0.0186–0.0659	11
ETHIONAMIDE	0.104–2.131	10
METHYL P-TOLYL SULFIDE	0.0048–10.2	10
FENTHION	0.145–0.351	9
MERCAPTOIMIDAZOLE	0.018–0.0527	9
NADPH	0.0031–0.132	9
TRIMETHYLAMINE	0.0015–0.58	9
SULINDAC SULFIDE	0.0101–0.0163	8
CHLORPROMAZINE	0.022–0.08	7
IMIPRAMINE	0.0047–0.02	7
L-METHIONINE	2.8–48	6
10-[(N,N-DIMETHYLAMINOOCTYL)-2-(TRIFLUOROMETHYL)	15–38	5

Catalyzed reactions (Rhea), 1 shown:

• N,N-dimethylaniline + NADPH + O2 + H(+) = N,N-dimethylaniline N-oxide + NADP(+) + H2O (RHEA:24468)

UniProt features (15 total): sequence variant 8, binding site 5, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P31512-F1	91.52	0.81

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5): 9–13; 32; 40–41; 60–61; 195–198

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 226 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, GOBP_LIPID_MODIFICATION, E2F_Q4, MODULE_93, E2F_Q4_01, REACTOME_BIOLOGICAL_OXIDATIONS, E2F4DP1_01, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GOBP_NEGATIVE_REGULATION_OF_LIPID_METABOLIC_PROCESS, GOBP_NADPPLUS_METABOLIC_PROCESS, XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN, KYNG_DNA_DAMAGE_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_KETONE_METABOLIC_PROCESS

GO Biological Process (4): xenobiotic metabolic process (GO:0006805), xenobiotic catabolic process (GO:0042178), negative regulation of fatty acid oxidation (GO:0046322), energy homeostasis (GO:0097009)

GO Molecular Function (6): N,N-dimethylaniline monooxygenase activity (GO:0004499), flavin adenine dinucleotide binding (GO:0050660), NADP binding (GO:0050661), monooxygenase activity (GO:0004497), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (3): endoplasmic reticulum membrane (GO:0005789), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metabolic process	1
cellular response to xenobiotic stimulus	1
xenobiotic metabolic process	1
catabolic process	1
fatty acid oxidation	1
negative regulation of fatty acid metabolic process	1
regulation of fatty acid oxidation	1
multicellular organismal-level homeostasis	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	1
nucleotide binding	1
anion binding	1
adenyl nucleotide binding	1
oxidoreductase activity	1
binding	1
catalytic activity	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1682 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FMO4	LINC03043	A4D0Y5	380
FMO4	CYP2S1	Q96SQ9	375
FMO4	ADH1B	P00325	354
FMO4	SLC10A1	Q14973	350
FMO4	CYP2F1	P24903	350
FMO4	CCS	O14618	346
FMO4	CYP2C8	P10632	345
FMO4	ABCC2	Q92887	320
FMO4	CYP4B1	P13584	319
FMO4	TMEM212	A6NML5	306
FMO4	SLCO5A1	Q9H2Y9	303
FMO4	SLCO2A1	Q92959	303
FMO4	SLCO3A1	Q9UIG8	303
FMO4	SLCO6A1	Q86UG4	303
FMO4	CTXN2	P0C2S0	301

IntAct

5 interactions, top by confidence:

A	B	Type	Score
FMO4	RHBDD2	psi-mi:“MI:0915”(physical association)	0.560
FMO1	LDHC	psi-mi:“MI:0914”(association)	0.350
FMO4	RHBDD2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (4): FMO4 (Two-hybrid), FMO4 (Affinity Capture-MS), FMO4 (Affinity Capture-MS), FMO4 (Proximity Label-MS)

ESM2 similar proteins: A4IFM3, O14756, O54753, O54909, O55240, O60774, O75452, O75828, O88451, P16549, P17636, P31512, P32417, P36365, P36367, P49109, P50170, P50285, P55006, P97501, P97872, Q01740, Q0IH28, Q0VFE7, Q27979, Q3T001, Q3T0R4, Q566S6, Q58NB6, Q5R6U1, Q5R7A2, Q6IAN0, Q6IRI9, Q8HYJ9, Q8HYR6, Q8K2I3, Q8K3P0, Q8K4C0, Q8L9C4, Q8N5I4

Diamond homologs: A8MRX0, P31512, P63534, P9WN18, P9WN19, P9WQ14, P9WQ15, Q03460, Q05756, Q0DG35, Q0JKD0, Q28505, Q93Y23, Q94BV5, Q94K43, Q9C8T8, Q9C8U0, Q9FF12, Q9FLK4, Q9FWW3, Q9FWW6, Q9FWW9, Q9HFE4, Q9LV03, Q9RKB5, Q9SH25, Q9SS04, Q9SXD5, Q9SXD9, Q9SXE1, A0A0B5RNJ4, A3SLM3, A3VVZ4, B6BQB2, B8ANW0, B8EIZ7, P38866, Q10RE2, Q1V023, Q5LT63

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

98 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	76
Likely benign	6
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1758 predictions. Top by Δscore:

Variant	Effect	Δscore
1:171319923:G:GT	donor_gain	1.0000
1:171319948:G:GT	donor_gain	1.0000
1:171332855:G:GT	donor_gain	1.0000
1:171341412:GGGGA:G	acceptor_gain	1.0000
1:171314410:CAAGG:C	donor_loss	0.9900
1:171314411:AAGG:A	donor_loss	0.9900
1:171319929:A:AG	donor_gain	0.9900
1:171319958:G:GG	donor_gain	0.9900
1:171324136:A:AG	acceptor_gain	0.9900
1:171324137:G:GG	acceptor_gain	0.9900
1:171324298:CTGGT:C	donor_loss	0.9900
1:171324299:TGGTG:T	donor_loss	0.9900
1:171324301:G:GA	donor_loss	0.9900
1:171324302:TGA:T	donor_loss	0.9900
1:171324303:GAGT:G	donor_loss	0.9900
1:171324304:AGT:A	donor_loss	0.9900
1:171332890:GAT:G	donor_gain	0.9900
1:171332892:T:TG	donor_gain	0.9900
1:171337350:CCACA:C	acceptor_loss	0.9900
1:171337351:CACAG:C	acceptor_loss	0.9900
1:171337352:ACAGG:A	acceptor_loss	0.9900
1:171337353:CAG:C	acceptor_loss	0.9900
1:171337354:AGGAC:A	acceptor_loss	0.9900
1:171337355:G:T	acceptor_loss	0.9900
1:171337421:AAAAG:A	donor_loss	0.9900
1:171337422:AAAG:A	donor_loss	0.9900
1:171337423:AAG:A	donor_loss	0.9900
1:171337425:GGTAT:G	donor_loss	0.9900
1:171337427:T:A	donor_loss	0.9900
1:171341407:TCTCA:T	acceptor_loss	0.9900

AlphaMissense

3682 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:171319946:T:A	W41R	0.993
1:171319946:T:C	W41R	0.993
1:171324254:C:G	C146W	0.992
1:171323063:G:C	K64N	0.991
1:171323063:G:T	K64N	0.991
1:171324189:T:A	W125R	0.989
1:171324189:T:C	W125R	0.989
1:171319948:G:C	W41C	0.986
1:171319948:G:T	W41C	0.986
1:171334740:G:C	R386P	0.986
1:171331672:A:C	S173R	0.983
1:171331674:T:A	S173R	0.983
1:171331674:T:G	S173R	0.983
1:171332718:A:C	S213R	0.983
1:171332720:T:A	S213R	0.983
1:171332720:T:G	S213R	0.983
1:171334742:T:A	W387R	0.983
1:171334742:T:C	W387R	0.983
1:171319915:C:G	C30W	0.982
1:171319862:A:C	S13R	0.981
1:171319864:T:A	S13R	0.981
1:171319864:T:G	S13R	0.981
1:171323079:A:C	S70R	0.981
1:171323081:T:A	S70R	0.981
1:171323081:T:G	S70R	0.981
1:171341577:G:C	R472P	0.981
1:171323143:T:C	L91P	0.979
1:171319947:G:C	W41S	0.978
1:171331651:T:C	F166L	0.977
1:171331653:T:A	F166L	0.977

dbSNP variants (sampled 300 via entrez): RS1000319188 (1:171338499 C>T), RS1000427504 (1:171317792 T>A,C), RS1000600894 (1:171327271 A>G), RS1000653502 (1:171326902 A>T), RS1000733598 (1:171329860 C>A,T), RS1000811787 (1:171332447 G>A), RS1000844981 (1:171314842 C>A), RS1000904062 (1:171315442 T>TG), RS1001482246 (1:171317130 C>G), RS1001534684 (1:171317319 A>C), RS1001549024 (1:171326342 A>T), RS1001605807 (1:171320128 A>G), RS1001797717 (1:171323192 G>A,T), RS1001942871 (1:171321527 C>G), RS1002123412 (1:171336039 G>C)

Disease associations

OMIM: gene MIM:136131 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): trimethylaminuria (MONDO:0011182)

Orphanet (1): NON RARE IN EUROPE: Trimethylaminuria (Orphanet:35056)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0003614	Trimethylaminuria

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST003075_1	Cognitive decline rate in late mild cognitive impairment	1.000000e-06
GCST003075_100	Cognitive decline rate in late mild cognitive impairment	9.000000e-07
GCST003075_101	Cognitive decline rate in late mild cognitive impairment	2.000000e-10
GCST003075_9	Cognitive decline rate in late mild cognitive impairment	2.000000e-10
GCST004125_11	Type 2 diabetes (age of onset)	4.000000e-06
GCST006586_46	Urinary albumin excretion	1.000000e-08
GCST007354_22	Intracranial aneurysm	2.000000e-10
GCST009733_124	Urinary metabolite levels in chronic kidney disease	2.000000e-15
GCST009733_176	Urinary metabolite levels in chronic kidney disease	2.000000e-16
GCST009733_209	Urinary metabolite levels in chronic kidney disease	1.000000e-17

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007710	cognitive decline measurement
EFO:0004285	albuminuria
EFO:0005116	urinary metabolite measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3542432 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

4 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2020870	FMO2		0.00	0
rs2076322	FMO4		0.00	0
rs7512785	FMO2		0.00	0
rs7515157	FMO2		0.00	0

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, increases expression	2
Acetaminophen	decreases expression	2
Benzo(a)pyrene	affects methylation, decreases expression	2
Nickel	decreases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	decreases expression	2
GSK-J4	decreases expression	1
lasiocarpine	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
bisphenol A	increases expression, affects cotreatment	1
chlortoluron	decreases expression	1
senecionine	decreases expression	1
senkirkine	decreases expression	1
heliotrine	decreases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
entinostat	increases expression	1
NCX 4040	increases expression	1
bisphenol S	affects cotreatment, increases expression	1
incobotulinumtoxinA	increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Calcitriol	increases expression, affects cotreatment	1
Cisplatin	decreases expression	1
Cytarabine	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Ozone	affects expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4153816	ADMET	Drug metabolism in human hepatocytes assessed as formation of FMO-mediated N,N-Dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide	The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one). — J Med Chem

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01793168	Not specified	RECRUITING	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford